Parnell Pharmaceuticals Holdings EBITDA 2014-2018 | PARNF
Parnell Pharmaceuticals Holdings ebitda from 2014 to 2018. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Parnell Pharmaceuticals Holdings Annual EBITDA
(Millions of US $) |
| 2021 |
$8 |
| 2020 |
$1 |
| 2019 |
$4 |
| 2018 |
$7 |
| 2017 |
$-2 |
| 2016 |
$-11 |
| 2015 |
$-8 |
| 2014 |
$7 |
| 2014 |
$0 |
| 2013 |
$-5 |
| 2013 |
$0 |
| 2012 |
$-1 |
Parnell Pharmaceuticals Holdings Quarterly EBITDA
(Millions of US $) |
| 2018-03-31 |
$0 |
| 2017-12-31 |
|
| 2016-12-31 |
$4 |
| 2016-09-30 |
$4 |
| 2015-12-31 |
$3 |
| 2015-09-30 |
$3 |
| 2015-06-30 |
$3 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$1 |
| 2014-06-30 |
|
| 2014-03-31 |
$1 |
| 2013-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
